Agreement Between HCi Viocare and Carilex for the Development and Commercialization of a Genuinely Smart Mattress, Brings a Revolution in Hospital Care

GLASGOW, SCOTLAND--(Marketwired - Sep 29, 2016) - HCi Viocare (OTCQB: VICA), is pleased to announce that its wholly owned subsidiary, HCi Viocare Technologies, has signed a licensing agreement with Carilex Medical Inc., a leading medical mattresses manufacturer with global presence. The two companies combined forces in setting a common goal to redefine the way in which nursing monitoring and care of bedridden patients takes place, incorporating the groundbreaking Flexisense™ technology into a Carilex special production line of medical mattresses and delivering to the hospitals a series of truly smart mattresses.

Even the most modern hospitals in the world face significant weaknesses in the effective treatment of bedridden patients, as there is no automated alert and monitoring system for caregivers. Furthermore, some modern mattresses present limited automation in individual functions, in contrast to the Flexisense™ solution, which is holistic.

With 25 years of experience, Carilex builds on expertise, extending their lead over competition by developing state-of-the-art technology on anti-decubitus mattresses. Carilex invests highly in innovation and has always worked tirelessly with medical institutions worldwide to gain critical insight into the needs of patients and clinicians. Having the full-control of in-house manufacturing, Carilex provides unparalleled products in wound care management in the form of a comprehensive product line proven in the prevention and treatment of pressure sores and wounds.

HCi Viocare's proprietary technology Flexisense™ is a pressure and shear sensor system, a ground breaking technology with many different applications in the health, sports and everyday life sectors. Flexisense™ uses a multitude of micro sensors to measure pressure and shear forces, providing real time and on demand information, wirelessly, to any smart device. The different configurations of Flexisense™ in a mattress can extend to numerous usages and benefits, making it ideal for optimizing the care provided to immobilized patients.

Dr. Christos Kapatos, HCi Viocare's co-founder and CTO stated: "We are truly excited for our cooperation with Carilex Medical. We deeply appreciate their innovative and, at the same time, human-centric and qualitative profile. The medical mattress is one of the most interesting applications of Flexisense™, as it will fill a big gap in the market, providing real solutions to the hospitals and dramatically improving the patients' quality of life."

Mindy Kuei, Deputy Marketing Director of Carilex Medical Group, stated, "With HCi Viocare, we share the same vision of bringing innovation into everyday life. Our goal is to create a new product line of smart mattresses, empowered by Flexisense™ that will revolutionize the standard of patient care."

About HCi Viocare

HCi Viocare (OTCQB: VICA), has a dual, complementary business model of 1) creating the first cross-border independent chain of Prosthetics & Orthotics (P&O) and Diabetic Foot clinics in Europe and the Middle East and 2) developing a wide portfolio of proprietary hardware solutions with first in line the Flexisense™ sensor system, aiming to empower the user by providing on demand information in the fields of Digital Health, Prosthetics, Orthotics, Diabetes, Assistive Devices, Sports and Wellbeing, and licensing to established industry participants. HCi Viocare is listed on the OTC Markets in the USA, has its executive office in Athens, Greece and R&D center in Glasgow, UK.

Please visit: www.hciviocare.com
http://flexisense.hciviocare.com/

Forward Looking Statements

This press release contains forward-looking statements. Forward-looking statements are subject to risks, uncertainties and assumptions and are identified by words such as "expects", "intends", "estimates", "projects", "anticipates", "believes", "could", and other similar words. All statements addressing product performance, events, or developments that the Company expects or anticipates will occur in the future are forward-looking statements, including but not limited to future developments in the areas of athletic shoes and the information and performance of the company's technology in such applications. Because the statements are forward-looking, they should be evaluated in light of important risk factors and uncertainties, some of which are described in the Company's Quarterly, Annual and Current Reports filed with the United States Securities and Exchange Commission (the "SEC"). Should one or more of these risks or uncertainties materialize, or should any of the Company's underlying assumptions prove correct, actual results may vary materially from those currently anticipated. In addition, undue reliance should not be placed on Company's forward-looking statements. In particular, the Company has acquired its first operational Prosthetics & Orthotics (P&O) clinic and is continuing development efforts for its other biomedical technologies, including a "smart insole" and its Flexisense TM sensing technology with several potential applications. There is no assurance that the Company will be successful in its ongoing expansion and development efforts, or that it will find suitable commercialization partners for its technologies. Except as required by law, HCi Viocare disclaims any obligation to update or publicly announce any revisions to any of the forward-looking statements contained in this press release. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. No stock exchange, securities commission or other regulatory body has reviewed nor accepts responsibility for the adequacy or accuracy of this release. Investors are advised to carefully review the reports and documents that HCi Viocare files from time to time with the SEC, including its Annual, Quarterly and Current Reports.